{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:05:47Z","timestamp":1788998747466,"version":"build-2803163510"},"reference-count":61,"publisher":"The Endocrine Society","issue":"5","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32DK07245"],"award-info":[{"award-number":["T32DK07245"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ZIA DK075121-04"],"award-info":[{"award-number":["ZIA DK075121-04"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cooperative Research and Development Agreement","award":["#02241"],"award-info":[{"award-number":["#02241"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Increased tissue cortisol availability has been implicated in abnormal glucose and fat metabolism in patients with obesity, metabolic syndrome, and type 2 diabetes (T2DM). Our objective was to evaluate whether blockade of glucocorticoid receptor (GR) with mifepristone ameliorates insulin resistance (IR) in overweight\/obese subjects with glucose intolerance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a randomized, double-blinded, placebo-controlled, crossover study in overweight\/obese individuals (n\u2005=\u200516, 44% female) with prediabetes or mild T2DM but not clinical hypercortisolism. Mifepristone (50 mg every 6 h) or placebo was administered for 9 days, followed by crossover to the other treatment arm after a washout period of 6 to 8weeks. At baseline and following each treatment, oral glucose tolerance test (OGTT) and frequently sampled intravenous glucose tolerance test (FSIVGTT) were performed. Insulin sensitivity was measured using FSIVGTT [primary outcome: insulin sensitivity index (SI)] and OGTT [Matsuda index (MI) and oral glucose insulin sensitivity index (OGIS)]. Hepatic and adipose insulin resistance were assessed using hepatic insulin resistance index (HIRI), and adipose tissue insulin sensitivity index (Adipo-SI) and adipo-IR, derived from the FSIVGTT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mifepristone administration did not alter whole-body glucose disposal indices of insulin sensitivity (SI, MI, and OGIS). GR blockade significantly improved Adipo-SI (61.7\u2005\u00b1\u200532.9 vs 42.8\u2005\u00b1\u200523.9; P\u2005=\u20050.002) and reduced adipo-IR (49.9\u2005\u00b1\u200545.9 vs 65.5\u2005\u00b1\u200543.8; P\u2005=\u20050.004), and HIRI (50.2\u2005\u00b1\u200538.7 vs 70.0\u2005\u00b1\u200544.3; P\u2005=\u20050.08). Mifepristone increased insulin clearance but did not affect insulin secretion or \u03b2-cell glucose sensitivity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Short-term mifepristone administration improves adipose and hepatic insulin sensitivity among obese individuals with hyperglycemia without hypercortisolism.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab046","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T23:23:26Z","timestamp":1611876206000},"page":"1501-1515","source":"Crossref","is-referenced-by-count":23,"title":["Mifepristone Improves Adipose Tissue Insulin Sensitivity in Insulin Resistant Individuals"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-1381","authenticated-orcid":false,"given":"Sriram","family":"Gubbi","sequence":"first","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4198-1055","authenticated-orcid":false,"given":"Ranganath","family":"Muniyappa","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8954-4535","authenticated-orcid":false,"given":"Susmeeta T","family":"Sharma","sequence":"additional","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA"},{"name":"MedStar Washington Hospital Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivraj","family":"Grewal","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raven","family":"McGlotten","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"},{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette K","family":"Nieman","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA"},{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"issue":"1","key":"2021122205024391300_CIT0001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s125-002-8244-y","article-title":"Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans","volume":"45","author":"Hollingdal","year":"2002","journal-title":"Diabetologia."},{"issue":"8","key":"2021122205024391300_CIT0002","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI119743","article-title":"Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids","volume":"100","author":"Delaunay","year":"1997","journal-title":"J Clin Invest."},{"issue":"7","key":"2021122205024391300_CIT0003","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1210\/jc.2010-0119","article-title":"Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects","volume":"95","author":"Hansen","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122205024391300_CIT0004","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1210\/er.2016-1105","article-title":"Glucose metabolism abnormalities in cushing syndrome: from molecular basis to clinical management","volume":"38","author":"Scaroni","year":"2017","journal-title":"Endocr Rev."},{"issue":"1","key":"2021122205024391300_CIT0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1210\/jcem-54-1-131","article-title":"Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action","volume":"54","author":"Rizza","year":"1982","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122205024391300_CIT0006","doi-asserted-by":"crossref","first-page":"E654","DOI":"10.1152\/ajpendo.00453.2006","article-title":"Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism","volume":"292","author":"Qi","year":"2007","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"1","key":"2021122205024391300_CIT0007","doi-asserted-by":"crossref","first-page":"E102","DOI":"10.1152\/ajpendo.00566.2002","article-title":"Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects","volume":"286","author":"Nielsen","year":"2004","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"10","key":"2021122205024391300_CIT0008","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1359\/jbmr.2001.16.10.1879","article-title":"Glucocorticoid excess during adolescence leads to a major persistent deficit in bone mass and an increase in central body fat","volume":"16","author":"Abad","year":"2001","journal-title":"J Bone Miner Res."},{"issue":"9996","key":"2021122205024391300_CIT0009","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing\u2019s syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet."},{"issue":"7","key":"2021122205024391300_CIT0010","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"2021122205024391300_CIT0011","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/eje.0.1490543","article-title":"Hepatic steatosis in Cushing\u2019s syndrome: a radiological assessment using computed tomography","volume":"149","author":"Rockall","year":"2003","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2021122205024391300_CIT0012","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-61-3-536","article-title":"Successful treatment of Cushing\u2019s syndrome with the glucocorticoid antagonist RU 486","volume":"61","author":"Nieman","year":"1985","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2021122205024391300_CIT0013","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.2337\/dc13-0246","article-title":"Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects","volume":"36","author":"Wallia","year":"2013","journal-title":"Diabetes Care."},{"issue":"6","key":"2021122205024391300_CIT0014","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122205024391300_CIT0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/obr.12229","article-title":"Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies","volume":"16","author":"O\u2019Neill","year":"2015","journal-title":"Obes Rev."},{"issue":"8","key":"2021122205024391300_CIT0016","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1210\/jc.2009-0370","article-title":"Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis","volume":"94","author":"Anagnostis","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122205024391300_CIT0017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1196\/annals.1367.009","article-title":"The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome","volume":"1083","author":"Pasquali","year":"2006","journal-title":"Ann N Y Acad Sci."},{"issue":"5549","key":"2021122205024391300_CIT0018","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1126\/science.1066285","article-title":"A transgenic model of visceral obesity and the metabolic syndrome","volume":"294","author":"Masuzaki","year":"2001","journal-title":"Science."},{"issue":"2","key":"2021122205024391300_CIT0019","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.mce.2009.09.024","article-title":"Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease","volume":"316","author":"Morton","year":"2010","journal-title":"Mol Cell Endocrinol."},{"issue":"2","key":"2021122205024391300_CIT0020","doi-asserted-by":"crossref","first-page":"E351","DOI":"10.1152\/ajpendo.90769.2008","article-title":"Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss","volume":"296","author":"Purnell","year":"2009","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"9","key":"2021122205024391300_CIT0021","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1210\/jc.2004-0153","article-title":"Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins","volume":"89","author":"Kannisto","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021122205024391300_CIT0022","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1210\/jc.2003-030286","article-title":"Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity","volume":"88","author":"Wake","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122205024391300_CIT0023","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.beem.2007.07.003","article-title":"Modulation of glucocorticoid action and the treatment of type-2 diabetes","volume":"21","author":"Tomlinson","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"7","key":"2021122205024391300_CIT0024","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2337\/dc09-2315","article-title":"The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care."},{"issue":"1","key":"2021122205024391300_CIT0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/jpet.104.081257","article-title":"Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes","volume":"314","author":"Jacobson","year":"2005","journal-title":"J Pharmacol Exp Ther."},{"issue":"2","key":"2021122205024391300_CIT0026","first-page":"379","article-title":"RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism","volume":"80","author":"Garrel","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122205024391300_CIT0027","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/j.1550-8528.1995.tb00143.x","article-title":"Blockade of the glucocorticoid receptor with RU 486: effects in vitro and in vivo on human adipose tissue lipoprotein lipase activity","volume":"3","author":"Ottosson","year":"1995","journal-title":"Obes Res."},{"issue":"4","key":"2021122205024391300_CIT0028","doi-asserted-by":"crossref","first-page":"e1835","DOI":"10.1210\/clinem\/dgaa070","article-title":"Reduced insulin clearance and insulin-degrading enzyme activity contribute to hyperinsulinemia in African Americans","volume":"105","author":"Fosam","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122205024391300_CIT0029","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2337\/dc06-1519","article-title":"Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test","volume":"30","author":"Abdul-Ghani","year":"2007","journal-title":"Diabetes Care."},{"issue":"4","key":"2021122205024391300_CIT0030","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1210\/jc.2017-00047","article-title":"How to measure adipose tissue insulin sensitivity","volume":"102","author":"S\u00f8ndergaard","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122205024391300_CIT0031","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2337\/diabetes.51.6.1867","article-title":"Sensitivity to acute insulin-mediated suppression of plasma free fatty acids is not a determinant of fasting VLDL triglyceride secretion in healthy humans","volume":"51","author":"Carpentier","year":"2002","journal-title":"Diabetes."},{"issue":"6","key":"2021122205024391300_CIT0032","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.fertnstert.2012.08.025","article-title":"Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome","volume":"98","author":"Trottier","year":"2012","journal-title":"Fertil Steril."},{"issue":"9","key":"2021122205024391300_CIT0033","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S0026-0495(99)90132-4","article-title":"Beta-cell function during insulin-modified intravenous glucose tolerance test successfully assessed by the C-peptide minimal model","volume":"48","author":"Toffolo","year":"1999","journal-title":"Metabolism."},{"issue":"1","key":"2021122205024391300_CIT0034","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00421.2006","article-title":"Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests","volume":"293","author":"Cobelli","year":"2007","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"24","key":"2021122205024391300_CIT0035","doi-asserted-by":"crossref","first-page":"e124912","DOI":"10.1172\/jci.insight.124912","article-title":"Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents","volume":"3","author":"Trico","year":"2018","journal-title":"JCI Insight."},{"issue":"6","key":"2021122205024391300_CIT0036","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2337\/diab.44.6.718","article-title":"Amelioration of high-fat feeding-induced insulin resistance in skeletal muscle with the antiglucocorticoid RU486","volume":"44","author":"Kusunoki","year":"1995","journal-title":"Diabetes."},{"issue":"10","key":"2021122205024391300_CIT0037","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.ijo.0800479","article-title":"RU-486 (Mifepristone) ameliorates diabetes but does not correct deficient beta-adrenergic signalling in adipocytes from mature C57BL\/6J-ob\/ob mice","volume":"21","author":"Gettys","year":"1997","journal-title":"Int J Obes Relat Metab Disord."},{"issue":"1","key":"2021122205024391300_CIT0038","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2337\/diabetes.54.1.32","article-title":"Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db\/db mice","volume":"54","author":"Liu","year":"2005","journal-title":"Diabetes."},{"issue":"1","key":"2021122205024391300_CIT0039","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1203\/00006450-200107000-00021","article-title":"Glucose production, gluconeogenesis, and insulin sensitivity in children and adolescents: an evaluation of their reproducibility","volume":"50","author":"Sunehag","year":"2001","journal-title":"Pediatr Res."},{"issue":"6","key":"2021122205024391300_CIT0040","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s001250051215","article-title":"Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes","volume":"42","author":"Hermans","year":"1999","journal-title":"Diabetologia."},{"issue":"1","key":"2021122205024391300_CIT0041","doi-asserted-by":"crossref","first-page":"e000415","DOI":"10.1136\/bmjdrc-2017-000415","article-title":"Insulin-sensitive and insulin-resistant obese and non-obese phenotypes: role in prediction of incident pre-diabetes in a longitudinal biracial cohort","volume":"5","author":"Owei","year":"2017","journal-title":"BMJ Open Diabetes Res Care."},{"issue":"6","key":"2021122205024391300_CIT0042","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1161\/01.STR.0000071108.00234.0E","article-title":"Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke","volume":"34","author":"Kernan","year":"2003","journal-title":"Stroke."},{"key":"2021122205024391300_CIT0043","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13098-018-0365-y","article-title":"Accuracy of insulin resistance indices for metabolic syndrome: a cross-sectional study in adults","volume":"10","author":"Antoniolli","year":"2018","journal-title":"Diabetol Metab Syndr."},{"issue":"12","key":"2021122205024391300_CIT0044","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.2337\/diacare.26.12.3320","article-title":"Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism","volume":"26","author":"Ascaso","year":"2003","journal-title":"Diabetes Care."},{"issue":"12","key":"2021122205024391300_CIT0045","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.81.12.3879","article-title":"RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day","volume":"81","author":"Gaillard","year":"1984","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2021122205024391300_CIT0046","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1152\/ajpendo.00645.2007","article-title":"Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage","volume":"294","author":"Muniyappa","year":"2008","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"11","key":"2021122205024391300_CIT0047","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.metabol.2011.06.012","article-title":"The effects of glucocorticoids on adipose tissue lipid metabolism","volume":"60","author":"Peckett","year":"2011","journal-title":"Metabolism."},{"issue":"4","key":"2021122205024391300_CIT0048","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol Rev."},{"issue":"11","key":"2021122205024391300_CIT0049","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1074\/jbc.M111.294124","article-title":"Angiopoietin-like 4 (Angptl4) protein is a physiological mediator of intracellular lipolysis in murine adipocytes","volume":"287","author":"Gray","year":"2012","journal-title":"J Biol Chem."},{"issue":"8","key":"2021122205024391300_CIT0050","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1210\/me.2008-0464","article-title":"Direct effect of glucocorticoids on lipolysis in adipocytes","volume":"23","author":"Xu","year":"2009","journal-title":"Mol Endocrinol."},{"issue":"7","key":"2021122205024391300_CIT0051","doi-asserted-by":"crossref","first-page":"G760","DOI":"10.1152\/ajpgi.00030.2014","article-title":"Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with type 2 diabetes with and without fatty liver","volume":"307","author":"Macfarlane","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"issue":"12","key":"2021122205024391300_CIT0052","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1055\/s-0029-1234071","article-title":"Effect of RU486 on hepatic and adipocyte gene expression improves diabetes control in obesity-type 2 diabetes","volume":"41","author":"Taylor","year":"2009","journal-title":"Horm Metab Res."},{"issue":"2","key":"2021122205024391300_CIT0053","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00125-010-1956-9","article-title":"Tissue-specific dysregulation of hexose-6-phosphate dehydrogenase and glucose-6-phosphate transporter production in db\/db mice as a model of type 2 diabetes","volume":"54","author":"Wang","year":"2011","journal-title":"Diabetologia."},{"issue":"4","key":"2021122205024391300_CIT0054","doi-asserted-by":"crossref","first-page":"e60984","DOI":"10.1371\/journal.pone.0060984","article-title":"Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study","volume":"8","author":"Debono","year":"2013","journal-title":"PLoS One."},{"issue":"8","key":"2021122205024391300_CIT0055","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4158\/EP-2019-0047","article-title":"Mifepristone treatment for mild autonomous cortisol secretion due to adrenal adenomas: A Pilot Study","volume":"25","author":"Belokovskaya","year":"2019","journal-title":"Endocr Pract."},{"issue":"5","key":"2021122205024391300_CIT0056","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/jc.2011-2813","article-title":"Impact of mifepristone, a glucocorticoid\/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function","volume":"97","author":"Page","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122205024391300_CIT0057","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1210\/jc.2002-021194","article-title":"Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes","volume":"88","author":"Andrews","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122205024391300_CIT0058","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2337\/db16-1356","article-title":"Glucocorticoids reprogram \u03b2-cell signaling to preserve insulin secretion","volume":"67","author":"Fine","year":"2018","journal-title":"Diabetes."},{"issue":"4","key":"2021122205024391300_CIT0059","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1530\/EJE-09-1034","article-title":"Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men","volume":"162","author":"van Raalte","year":"2010","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021122205024391300_CIT0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/cs0830171","article-title":"Glucocorticoids and blood pressure: a role for the cortisol\/cortisone shuttle in the control of vascular tone in man","volume":"83","author":"Walker","year":"1992","journal-title":"Clin Sci (Lond)."},{"issue":"1","key":"2021122205024391300_CIT0061","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/jcem-59-1-25","article-title":"The new steroid analog RU 486 inhibits glucocorticoid action in man","volume":"59","author":"Bertagna","year":"1984","journal-title":"J Clin Endocrinol Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab046\/36320985\/dgab046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/5\/1501\/41849563\/dgab046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/5\/1501\/41849563\/dgab046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T05:07:24Z","timestamp":1640149644000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/5\/1501\/6122543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,1,28]]},"published-print":{"date-parts":[[2021,4,23]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab046","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,1,28]]}}}